Competing Endogenous RNA Networks in Ovarian Cancer: from Bench to Bedside

Overview

Journal EXCLI J

Specialty Biology

Date 2025 Feb 19

PMID 39967908

Authors

Roghaiyeh Derogar

Fatemeh Nejadi Orang

Mahdi Abdoli Shadbad

Affiliations

Soon will be listed here.

Abstract

Epithelial ovarian cancer is responsible for the majority of ovarian malignancies, and its highly invasive nature and chemoresistant development have been major obstacles to treating patients with mainstream treatments. In recent decades, the significance of microRNAs (miRNAs), circular RNAs (circRNAs), long non-coding RNAs (lncRNAs), and competing endogenous RNAs (ceRNAs) has been highlighted in ovarian cancer development. This hidden language between these RNAs has led to the discovery of enormous regulatory networks in ovarian cancer cells that substantially affect gene expression. Aside from providing ample opportunities for targeted therapies, circRNA- and lncRNA-mediated ceRNA network components provide invaluable biomarkers. The current study provides a comprehensive and up-to-date review of the recent findings on the significance of these ceRNA networks in the hallmarks of ovarian cancer oncogenesis, treatment, diagnosis, and prognosis. Also, it provides the authorship with future perspectives in the era of single-cell RNA sequencing and personalized medicine.

References

Motohara T, Yoshida G, Katabuchi H . The hallmarks of ovarian cancer stem cells and niches: Exploring their harmonious interplay in therapy resistance. Semin Cancer Biol. 2021; 77:182-193. DOI: 10.1016/j.semcancer.2021.03.038. View

Zheng Q, Dai X, Fang W, Zheng Y, Zhang J, Liu Y . Overexpression of microRNA-367 inhibits angiogenesis in ovarian cancer by downregulating the expression of LPA1. Cancer Cell Int. 2020; 20:476. PMC: 7531134. DOI: 10.1186/s12935-020-01551-x. View

An J, Lv W, Zhang Y . LncRNA NEAT1 contributes to paclitaxel resistance of ovarian cancer cells by regulating ZEB1 expression via miR-194. Onco Targets Ther. 2017; 10:5377-5390. PMC: 5691924. DOI: 10.2147/OTT.S147586. View

Chen Z, Guo X, Sun S, Lu C, Wang L . Serum miR-125b levels associated with epithelial ovarian cancer (EOC) development and treatment responses. Bioengineered. 2020; 11(1):311-317. PMC: 7161537. DOI: 10.1080/21655979.2020.1736755. View

Duan L, Yan Y, Wang G, Xing Y, Sun J, Wang L . ΜiR-182-5p functions as a tumor suppressor to sensitize human ovarian cancer cells to cisplatin through direct targeting the cyclin dependent kinase 6 (CDK6). J BUON. 2020; 25(5):2279-2286. View

Le P, Romano G, Nana-Sinkam P, Acunzo M . Non-Coding RNAs in Cancer Diagnosis and Therapy: Focus on Lung Cancer. Cancers (Basel). 2021; 13(6). PMC: 8003033. DOI: 10.3390/cancers13061372. View

Liu C, Zhao S, Lv Z, Zhao X . Promoting action of long non-coding RNA small nucleolar RNA host gene 4 in ovarian cancer. Acta Biochim Pol. 2023; 70(1):59-68. DOI: 10.18388/abp.2020_6141. View

Ribatti D, Tamma R, Annese T . Epithelial-Mesenchymal Transition in Cancer: A Historical Overview. Transl Oncol. 2020; 13(6):100773. PMC: 7182759. DOI: 10.1016/j.tranon.2020.100773. View

Ding L, Cao J, Lin W, Chen H, Xiong X, Ao H . The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer. Int J Mol Sci. 2020; 21(6). PMC: 7139603. DOI: 10.3390/ijms21061960. View

10.

Cui S, Li C . RHPN1‑AS1 promotes ovarian carcinogenesis by sponging miR‑485‑5p and releasing TPX2 mRNA. Oncol Rep. 2021; 45(6). PMC: 8082340. DOI: 10.3892/or.2021.8062. View

11.

Gu L, Li Q, Liu H, Lu X, Zhu M . Long Noncoding RNA TUG1 Promotes Autophagy-Associated Paclitaxel Resistance by Sponging miR-29b-3p in Ovarian Cancer Cells. Onco Targets Ther. 2020; 13:2007-2019. PMC: 7065918. DOI: 10.2147/OTT.S240434. View

12.

Huang R, Zhu L, Zhang Y . XIST lost induces ovarian cancer stem cells to acquire taxol resistance via a KMT2C-dependent way. Cancer Cell Int. 2020; 20:436. PMC: 7487955. DOI: 10.1186/s12935-020-01500-8. View

13.

Lv W, Jia Y, Wang J, Duan Y, Wang X, Liu T . Long non-coding RNA SNHG10 upregulates BIN1 to suppress the tumorigenesis and epithelial-mesenchymal transition of epithelial ovarian cancer via sponging miR-200a-3p. Cell Death Discov. 2022; 8(1):60. PMC: 8837780. DOI: 10.1038/s41420-022-00825-9. View

14.

Suh D, Kim M, Kim H, Kim M, Kim H, Chung H . Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer. Clin Exp Med. 2013; 14(3):345-53. DOI: 10.1007/s10238-013-0250-9. View

15.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

16.

Liu Y, Fu X, Wang X, Liu Y, Song X . Long non‑coding RNA OIP5‑AS1 facilitates the progression of ovarian cancer via the miR‑128‑3p/CCNG1 axis. Mol Med Rep. 2021; 23(5). PMC: 8008222. DOI: 10.3892/mmr.2021.12027. View

17.

Sestito R, Cianfrocca R, Tocci P, Rosano L, Sacconi A, Blandino G . Targeting endothelin 1 receptor-miR-200b/c-ZEB1 circuitry blunts metastatic progression in ovarian cancer. Commun Biol. 2020; 3(1):677. PMC: 7666224. DOI: 10.1038/s42003-020-01404-3. View

18.

Lopez-Reig R, Lopez-Guerrero J . The hallmarks of ovarian cancer: proliferation and cell growth. EJC Suppl. 2020; 15:27-37. PMC: 7573473. DOI: 10.1016/j.ejcsup.2019.12.001. View

19.

Sheng Q, Zhang Y, Wang Z, Ding J, Song Y, Zhao W . Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells. Clin Exp Immunol. 2019; 200(1):45-52. PMC: 7066384. DOI: 10.1111/cei.13406. View

20.

Shadbad M, Ghorbaninezhad F, Hassanian H, Ahangar N, Hosseinkhani N, Derakhshani A . A scoping review on the significance of programmed death-ligand 1-inhibiting microRNAs in non-small cell lung treatment: A single-cell RNA sequencing-based study. Front Med (Lausanne). 2022; 9:1027758. PMC: 9659572. DOI: 10.3389/fmed.2022.1027758. View